维妥珠单抗 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "维妥珠单抗" in Chinese language version.

refsWebsite

Global rank Chinese rank

3doi.org

2^nd place

23^rd place

3web.archive.org

1^st place

2nih.gov

4^th place

5^th place

1books.google.com

3^rd place

8^th place

1ama-assn.org

3,257^th place

3,896^th place

1clinicaltrials.gov

5,225^th place

4,888^th place

1healio.com

low place

ama-assn.org (Global: 3,257^th place; Chinese: 3,896^th place)

Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab （页面存档备份，存于互联网档案馆）, American Medical Association.

books.google.com (Global: 3^rd place; Chinese: 8^th place)

Zibelman M, Borghaei H, Olszanski AJ. Harnessing Innate Immunity. Dubel S, Reichert JM (编). Handbook of Therapeutic Antibodies 2nd. John Wiley & Sons. 2014: 791 [2024-04-18]. ISBN 978-3-527-68244-7. doi:10.1002/9783527682423.ch27. （原始内容存档于2024-04-18）.

clinicaltrials.gov (Global: 5,225^th place; Chinese: 4,888^th place)

Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at ClinicalTrials.gov

doi.org (Global: 2^nd place; Chinese: 23^rd place)

Zibelman M, Borghaei H, Olszanski AJ. Harnessing Innate Immunity. Dubel S, Reichert JM (编). Handbook of Therapeutic Antibodies 2nd. John Wiley & Sons. 2014: 791 [2024-04-18]. ISBN 978-3-527-68244-7. doi:10.1002/9783527682423.ch27. （原始内容存档于2024-04-18）.
Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. October 2009, 114 (18): 3864–71. PMC 2773491 . PMID 19710501. doi:10.1182/blood-2009-06-228890.
Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, et al. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. British Journal of Haematology. June 2015, 169 (5): 701–10. PMC 7297055 . PMID 25847298. doi:10.1111/bjh.13354.

healio.com (Global: low place; Chinese: low place)

FDA grants orphan drug designation to veltuzumab for ITP. HemOnc Today. Healio.com. August 4, 2015 [2024-04-18]. （原始内容存档于2019-09-07）.

nih.gov (Global: 4^th place; Chinese: 5^th place)

ncbi.nlm.nih.gov

Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. October 2009, 114 (18): 3864–71. PMC 2773491 . PMID 19710501. doi:10.1182/blood-2009-06-228890.
Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, et al. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. British Journal of Haematology. June 2015, 169 (5): 701–10. PMC 7297055 . PMID 25847298. doi:10.1111/bjh.13354.

web.archive.org (Global: 1^st place; Chinese: 1^st place)

Zibelman M, Borghaei H, Olszanski AJ. Harnessing Innate Immunity. Dubel S, Reichert JM (编). Handbook of Therapeutic Antibodies 2nd. John Wiley & Sons. 2014: 791 [2024-04-18]. ISBN 978-3-527-68244-7. doi:10.1002/9783527682423.ch27. （原始内容存档于2024-04-18）.
Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab （页面存档备份，存于互联网档案馆）, American Medical Association.
FDA grants orphan drug designation to veltuzumab for ITP. HemOnc Today. Healio.com. August 4, 2015 [2024-04-18]. （原始内容存档于2019-09-07）.

维妥珠单抗 (Chinese Wikipedia)

ama-assn.org (Global: 3,257th place; Chinese: 3,896th place)

books.google.com (Global: 3rd place; Chinese: 8th place)

clinicaltrials.gov (Global: 5,225th place; Chinese: 4,888th place)

doi.org (Global: 2nd place; Chinese: 23rd place)